Clinical Trials Logo

Sturge-Weber Syndrome clinical trials

View clinical trials related to Sturge-Weber Syndrome.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05495269 Completed - Glaucoma Clinical Trials

Safety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP)

Start date: November 23, 2022
Phase: Phase 2
Study type: Interventional

Open-label study of an investigational product (IP), QLS-101, with 28-day every morning (QAM) dosing to both eyes (OU) in adolescents with SWS who have clinical evidence of glaucoma and/or ocular hypertension (OHT) related to SWS elevated EVP in at least one eye.

NCT ID: NCT04999618 Completed - Vascular Diseases Clinical Trials

A New Approach in Laser Surgery Using the Regenerative Solution in Children Diagnosed With Vascular Pathology

DOUBLE-SKIN
Start date: January 1, 2020
Phase: Phase 4
Study type: Interventional

Laser treatment (LT) is the first-line treatment for Vascular Pathology. However even when LT is based on the selective photothermolysis it causes the first-degree burns. While being typically benign by affecting only the epidermis, or outer layer of skin, the burn site is remaining red, dry, and very painful. As Haemoblock contains nanoparticles of silver and is known for both bactericidal and bacteriostatic effects, it likely decreases the potential for infection postoperatively. Furthermore, after fibrin replaces the superficial structure "Hemoblock-albumin", the polyacrylate matrix is plasmolyzed which initiates the cascade of signals required for the tissue regeneration processes. Objective of the study was to examine the effect of the Regenerative Solution "Hemoblock" in lowering postoperative complications in children diagnosed with Vascular Pathology undergoing a laser surgery if delivered with transdermal patches.

NCT ID: NCT04947124 Completed - Glaucoma Clinical Trials

A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101

Start date: October 19, 2021
Phase: Phase 2
Study type: Interventional

Safety and tolerability study of 2 concentrations of QLS-101 for adult subjects with Sturge Weber Syndrome (SWS)-related glaucoma due to elevated episcleral venous pressure (EVP).

NCT ID: NCT04447846 Completed - Clinical trials for Sturge-Weber Syndrome

Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome

Start date: October 14, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to better understand the utility of cannabidiol (CBD/ Epidiolex) for improving the treatment of cognitive impairments in Sturge-Weber syndrome (SWS).

NCT ID: NCT03047980 Completed - Clinical trials for Sturge-Weber Syndrome

Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome

Start date: January 2017
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this research study is to gain a preliminary understanding of the safety of sirolimus in Sturge-Weber syndrome (SWS) and determine best outcomes to be used to assess the utility of sirolimus for the treatment of cognitive impairments related to Sturge-Weber syndrome.

NCT ID: NCT02332655 Completed - Clinical trials for Sturge-Weber Syndrome

Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome

Start date: December 2014
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the tolerability and optimal dose of cannabidiol (CBD) as an simultaneous treatment in children and young adults with Sturge-Weber syndrome (SWS) and drug resistant epilepsy.

NCT ID: NCT02080624 Completed - Clinical trials for Sturge- Weber Syndrome

Efficacy and Safety Study of Topical Rapamycin Associated With Pulsed Dye Laser in Patients With Sturge-Weber Syndrome

RSW
Start date: January 2011
Phase: Phase 2
Study type: Interventional

Sturge-Weber syndrome (SWS) is a rare congenital neuro-cutaneous disorder considered as a rare or orphan disease. SWS is characterized by a capillary vascular malformation (CM) localized on the skin of the face, eyes and central nervous system. Given the localization and the extent of the CM, children with SWS are particularly prone to developing severe psychological problems. The standard treatment for CM is pulsed dye laser (PDL) although in these cases whitening of the lesion is rarely achieved. Combining topical rapamycin, a specific inhibitor of the mammalian target of rapamycin, with PDL is hypothesised to be a good therapeutic option in these patients.

NCT ID: NCT01364857 Completed - Port Wine Stain Clinical Trials

French National Cohort of Children With Port Wine Stain

CONAPE
Start date: November 2010
Phase: N/A
Study type: Interventional

Port Wine Stain on a limb can be either isolated or associated with complications (venous or orthopedic impairment, arteriovenous malformations), leading sometimes to complex syndromes (Klippel-Trenaunay syndrome,Parkes-Weber syndrome). Little is known about epidemiology of port wine stains: their evolution during the growth of the child, the frequency of complications, genetic data, and prognostic factors. This prospective french national cohort will help for : description of the evolution of port wine stain and possible complications; prognostic factors for complications ; association with mutations of RASA1 gene; quality of life of these children. It will also help for global appreciation of the management of this disease in France.

NCT ID: NCT01345305 Completed - Clinical trials for Sturge-Weber Syndrome

Biomarker Development in Sturge-Weber Syndrome

Pilot
Start date: July 2010
Phase:
Study type: Observational

This is a study of 40 individuals with Sturge-Weber Syndrome (SWS) brain and/or eye involvement. It will examine the test-retest reliability of the following clinical tests: 1. Quantitative EEG 2. Transcranial Doppler 3. Medical Rehabilitation Scales 4. Optical Coherence Tomography

NCT ID: NCT00639730 Completed - Epilepsy Clinical Trials

Use of the Atkins Diet for Children With Sturge Weber Syndrome

Start date: May 2006
Phase: Phase 1
Study type: Interventional

This research is being done to find out if the Atkins Diet can be used safely and effectively to reduce seizures in children who have Sturge Weber syndrome. The ketogenic diet is a proven therapy for epilepsy, but can be difficult to use in children. The Atkins Diet is a high fat, high protein, low carbohydrate diet introduced in the 1970s to help with weight loss. It is different from the ketogenic diet in four major ways: no calorie restriction, no fluid restriction, no protein restriction, and is easy to start outside the hospital. People on the Atkins Diet become ketotic (produce high levels of ketones, a certain substance in the body), like patients on the ketogenic diet, and the investigators believe this may lead to seizure control. Children aged 2-18 with Sturge Weber syndrome and seizures at least monthly, who have used at least two anti-seizure drugs may join. 5 children in total will be enrolled.